Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,873 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04165941 | Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma(DRI) | active not recruiting | Phase 1 | 22 | University of Alabama at BirminghamOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT05400603 | Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma(Aflac-NBL-2002) | recruiting | Phase 1 | 24 | Emory UniversityOTHER |
| 1 |
| Dec 26, 2025 |
| clinicaltrials |
| NCT06803875 | Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma | recruiting | Phase 1 / Phase 2 | 42 | Roberto ChiarleOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07145047 | Clinical Study of Oncolytic Virus in Glioblastoma | recruiting | Phase 1 / Phase 2 | 20 | Mianyang Central HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03500991 | HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors | active not recruiting | Phase 1 | 10 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05686798 | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. | recruiting | Phase 1 | 18 | Henry Ford Health SystemOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05956821 | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | recruiting | Phase 1 / Phase 2 | 20 | University of MiamiOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT02932280 | Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | active not recruiting | Phase 1 / Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT03212742 | Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients(OLA-TMZ-RTE-01) | active not recruiting | Phase 1 / Phase 2 | 91 | Centre Francois BaclesseOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06961565 | PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas | recruiting | Phase 1 | 56 | Pasithea Therapeutics Corp.INDUSTRY | 3 | Dec 4, 2025 | clinicaltrials |
| NCT07264569 | Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 | recruiting | Phase 1 / Phase 2 | 42 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03687957 | rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide | active not recruiting | Phase 1 / Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03233152 | A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.(GlitIpNi) | active not recruiting | Phase 1 / Phase 2 | 110 | Universitair Ziekenhuis BrusselOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04299191 | Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 28 | Laminar PharmaceuticalsINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05768880 | Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors | active not recruiting | Phase 1 | 72 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06970145 | Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma | recruiting | Phase 1 / Phase 2 | 57 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07193628 | B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma | recruiting | Phase 1 | 14 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06132945 | A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain | active not recruiting | Phase 1 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT04319276 | Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma | active not recruiting | Phase 1 | 26 | Medical College of WisconsinOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT06455605 | D2C7-IT + 2141-V11 Combination Post-resection in rGBM | recruiting | Phase 1 | 46 | Darell BignerOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT04373785 | NG101m Adjuvant Therapy in Glioblastoma Patients | not yet recruiting | Phase 1 / Phase 2 | 52 | NeuGATE TheranosticsINDUSTRY | 1 | Oct 21, 2025 | clinicaltrials |
| NCT02508038 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | recruiting | Phase 1 | 46 | Mayo ClinicOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT06059690 | Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells | recruiting | Phase 1 / Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT05734560 | D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients | recruiting | Phase 1 / Phase 2 | 50 | Darell BignerOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT02062827 | Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma(M032-HSV-1) | active not recruiting | Phase 1 | 29 | University of Alabama at BirminghamOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05598853 | Intrathecal Double Checkpoint Inhibition(IT-IO) | active not recruiting | Phase 1 | 26 | University of ZurichOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05485753 | A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) | active not recruiting | Phase 1 / Phase 2 | 7 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT04446962 | LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)(LOC-R01) | active not recruiting | Phase 1 / Phase 2 | 118 | Institut CurieOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04772456 | Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas | recruiting | Phase 1 | 5 | University of Maryland, BaltimoreOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT03294954 | GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma(GINAKIT2) | recruiting | Phase 1 | 70 | Baylor College of MedicineOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07179328 | Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy | recruiting | Phase 1 | 10 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05698147 | Selinexor in Combination With MTX+Ritu to Treat R/R CNSL | recruiting | Phase 1 / Phase 2 | 30 | Tong Chen, MDOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07141732 | Combined Treatment of Patients With Newly Diagnosed Glioblastoma Using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System for Intraoperative Balloon Electronic Brachytherapy | recruiting | Phase 1 | 15 | Joint Stock Company European Medical CentreOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07158710 | Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation | recruiting | Phase 1 | 159 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06102525 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma | recruiting | Phase 1 / Phase 2 | 43 | Rznomics, Inc.OTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT04910022 | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 150 | Nerviano Medical SciencesINDUSTRY | 5 | Aug 19, 2025 | clinicaltrials |
| NCT06018363 | Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection | recruiting | Phase 1 / Phase 2 | 25 | Dushu Lake Hospital Affiliated to Soochow UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05222802 | A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) | active not recruiting | Phase 1 | 52 | Katmai Pharmaceuticals Inc.INDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT03672721 | IA Carboplatin + Radiotherapy in Relapsing GBM | recruiting | Phase 1 / Phase 2 | 35 | Université de SherbrookeOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 230 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT06343311 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)(STARLIGHT-1) | recruiting | Phase 1 / Phase 2 | 21 | Estrella Biopharma, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06213636 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).(BAH241) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07025018 | Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations | recruiting | Phase 1 | 52 | HutchmedINDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT01843413 | Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases | active not recruiting | Phase 1 | 33 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 26, 2025source: clinicaltrials